FDA Addresses 'Misinformation' Concerning Delayed Approval Of Lucira Health's COVID-19 & Flu Home Test

Vandana Singh
2 min read
2

  • The FDA provided additional information about the agency's interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc's (OTC: LHDXQ) COVID-19 & Flu Home test.

  • The statement comes due to concerns about the agency's length and timing of the EUA clearance and its bankruptcy filing, which said the delay in EUA financially hit the company.

  • In an investor report, Lucira blamed the FDA's "protracted" authorization process for its combination Covid and flu at-home test.

  • Lucira applied to the FDA for authorization of its novel test last May and expected to receive a thumbs-up by the end of summer before the flu season started. Canada authorized Lucira's test last August.

  • The FDA finally authorized Lucira's test two days after it filed for bankruptcy and past the flu season peak.

  • The statement said the agency had found a toxic substance in the test's first submission that could pose a risk to users. Eventually, the company redesigned the test.

  • In addition, the EUA request included only nine positive influenza A clinical samples that FDA considered insufficient to determine test performance and support authorization.

  • When Lucira resubmitted, the company included 35 samples instead of the requirement of 50.

  • "In lieu of collecting additional samples, the FDA worked with our partners at the National Institutes of Health (NIH) Independent Test Assessment Program (ITAP) to evaluate the company's ability to manufacture tests of known quality. This data supported authorization even with the lower than requested number of positive influenza A samples that were provided," the statement reads.

  • Since there were not enough cases of influenza B circulating at the time, the FDA used data from the authorization of Lucira's point-of-care test, which included influenza B samples from previous flu seasons.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article FDA Addresses 'Misinformation' Concerning Delayed Approval Of Lucira Health's COVID-19 & Flu Home Test originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories

  • Forget Nvidia: Jim Cramer Says This Company Could Be About to Cash In on Artificial Intelligence (AI) Data Centers

    Data center services are witnessing outsized demand as the AI revolution unfolds.

  • 'Dumb Money' Loses $13.1 Billion In Latest GameStop Stock Mania

    It appears GameStop meme investors got suckered — again. Investors who jumped into the latest online frenzy over shares of the struggling video game retailer lost $13.1 billion in just three days from the mania's high, says an Investor's Business Daily analysis of data from S&P Global Market Intelligence and MarketSurge. It's been a costly lesson for investors, some of which may have lost billions the last time on GameStop and other highly shorted stocks touted on social media.

  • Red Lobster Chain Goes Bankrupt After Unlimited Shrimp Deal

    (Bloomberg) -- Seafood restaurant chain Red Lobster filed for bankruptcy, succumbing to onerous leases, high labor costs and a disastrous unlimited shrimp promotion. Most Read from BloombergIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteSpeedier Wall Street Trades Are Putting Global Finance On EdgeSaudi Crown Prince Postpones Japan Trip Over King’s HealthOne of the Last Big Bears on Wall Street Turns Bullish on US StocksEbrahim Raisi, Iranian President Confronting West, Dies at 63T

  • Jim Cramer Destroys New Starbucks CEO In Heated Interview, Says He Was "Stunned" As Its Former CEO Admits a "Fall From Grace"

    Despite a strong start to the year for stock markets, investors in Starbucks (NASDAQ:SBUX) have been left bitterly disappointed with its shares down by approximately 20% at the time of this writing. After the earnings miss, Laxman Narasimhan, the new CEO of Starbucks, appeared on Jim Cramer's Mad Money to try and explain both the results and the company's path forward. Don't Miss: Startup behind ‘the #1 free contractor app' grows 162% YoY, opens its doors for investors at a $100 minimum. Invest

  • Florida’s 125% Surge in Property-Insurance Bills Sows Havoc

    (Bloomberg) -- For Filicia Porter, the insurance bills were the final straw. They’d been climbing steeply for her assisted-living business as Florida was battered with ever more-powerful storms, and eventually, the numbers stopped adding up.Most Read from BloombergIran State TV Says ‘No Sign of Life’ at Helicopter Crash SiteSpeedier Wall Street Trades Are Putting Global Finance On EdgeSaudi Crown Prince Postpones Japan Trip Over King’s HealthOne of the Last Big Bears on Wall Street Turns Bullish

  • Jamie Dimon delivers startling message about inflation

    Consumer prices climbed 3.4% year-on-year in April.

  • Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks

    New indicators of a cooling economy eased inflation concerns, driving the S&P 500 to record highs last week. The index, which dropped around 4% in April, is now up 11% for the year. Will this momentum continue? Savita Subramanian, head of US Equity and Quantitative strategy at Bank of America, believes it will. She’s taking an upbeat stance on the current market outlook, and backs it with a look at long-term results from the past 300-plus quarters. “20 were recessionary, 13 were stagflationary,

  • Microsoft delivers an AI blow to Nvidia

    The software giant goes with Nvidia's rival for a platform of AI chips.

  • Ask an Advisor: I Don't Need Them ‘Dumped Into My Checking Account.' What Can I Do With RMDs?

    I am approaching the time when I'll take required minimum distributions (RMDs) from my individual retirement account (IRA). I am in a quandary about what I can do with this anticipated largesse of cash. I do not necessarily need the … Continue reading → The post Ask an Advisor: I Don't Need Them ‘Dumped Into My Checking Account.' What Can I Do With RMDs? appeared first on SmartAsset Blog.

  • Investors Heavily Search Super Micro Computer, Inc. (SMCI): Here is What You Need to Know

    Recently, Zacks.com users have been paying close attention to Super Micro (SMCI). This makes it worthwhile to examine what the stock has in store.